EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR tyrosine kinase (EGFR-TK) inhibitor with an IC50 of 0.054 µM. It also inhibits VEGFR-2, CK2alpha, topoisomerase IIbeta, and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13, and 3.61 µM, respectively. The compound promotes cell cycle arrest at the G2/M and pre-G1 phases and induces apoptosis in cancer cells [1].
